Login / Signup

A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.

Tine OttenbourgsToon Van GorpFrédéric KridelkaThaïs BaertHannelore DenysFrédéric SelleInge BaasAnne-Sophie Van RompuyDiether LambrechtsEls Van Nieuwenhuysen
Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
NCT05872204.
Keyphrases
  • phase ii
  • open label
  • estrogen receptor
  • clinical trial
  • phase iii
  • double blind
  • study protocol
  • phase ii study
  • placebo controlled
  • cross sectional
  • randomized controlled trial
  • metabolic syndrome
  • adipose tissue